Lumakras

Approved

Sotorasib

Amgen Inc. (AMGN)

Fast TrackBreakthrough TherapyLearn about designations

Approved

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in KRAS G12C NSCLC

View Full Landscape

Drug Information

Target Indication

KRAS G12C NSCLC

Mechanism of Action

KRAS G12C Inhibitor

Clinical Trial

NCT03600883

Last updated: 12/3/2025

Patent & Exclusivity

ActiveRLD

Latest Patent Expiry

Sep 15, 2040(13y 12m)

Patents Listed

Exclusivity

I-962NCEODE-352ODE-507ODE*

Application

NDA 214665

Source: FDA Orange Book

Regulatory Approvals

EMA1/6/2022

Lumykras

Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

Etanercept LiquidPhase 3

Rheumatoid Arthritis

TarlatamabPhase 3

Small Cell Lung Cancer

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts